EUVIMEDObjevte EUVIMED
Crossref

Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation

Xinyi Huang iD, David Salerno iD, Danielle Kovac iD, Jenna Scheffert, Jessica Hedvat iD, Bayleigh Carver, Jason Choe iD, Tara Shertel, Melana Yuzefpolskaya iD, Paolo C Colombo iD, Douglas L Jennings iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15420 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Xinyi Huang and 10 co-authors. Institution: Department of Pharmacy, New York Presbyterian Hospital, New York, New York, USA. Major MEDLINE topics: Heart Transplantation, Graft Rejection, Graft Survival, Immunosuppression Therapy. Cited 4 times so far (Crossref); 37 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.

Methods

This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.

Results

A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.

Conclusion

This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationGraft RejectionGraft SurvivalImmunosuppression TherapyImmunosuppressive AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisAdultPostoperative ComplicationsSurvival RateLiver TransplantationHeart-Lung TransplantationRisk FactorsKidney TransplantationDisease Management

Author keywords

heart–lung transplantationimmunosuppressive agentskidney transplantationliver transplantation

Substances

Immunosuppressive Agents

Authors and institutions

  • Department of Pharmacy, New York Presbyterian Hospital, New York, New York, USA.
  • Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA.
  • Division of Cardiology, Department of Medicine, New York Presbyterian Hospital, Columbia University, New York, New York, USA.

ORCID profiles: Xinyi Huang, David Salerno, Danielle Kovac, Jessica Hedvat, Jason Choe, Melana Yuzefpolskaya, Paolo C Colombo, Douglas L Jennings

Cite

APA

Huang, X., Salerno, D., Kovac, D., Scheffert, J., Hedvat, J., Carver, B., Choe, J., Shertel, T., Yuzefpolskaya, M., Colombo, P. C., & Jennings, D. L. (2024). Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.15420

Vancouver

Huang X, Salerno D, Kovac D, Scheffert J, Hedvat J, Carver B, et al. Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation. Clinical Transplantation. 2024. doi:10.1111/ctr.15420

BibTeX
@article{Huang2024,
  author = {Huang, Xinyi and Salerno, David and Kovac, Danielle and Scheffert, Jenna and Hedvat, Jessica and Carver, Bayleigh and Choe, Jason and Shertel, Tara and Yuzefpolskaya, Melana and Colombo, Paolo C and Jennings, Douglas L},
  title = {Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15420}
}
Start for free →